@AHS I honestly don’t know where the bottom is. There is obviously some inherent value above cash backing but even the cash is going to keep grinding down without a bonafide licence deal of substance.
The recent no-licence fee and no-milestone fee research agreement with Medicxi is IMO a complete joke and a clear indication to me that Starpharma are now negotiating from a position of weakness which does not bode well going forward.
All I know is that I was labelled a heretic for suggesting 3 years ago that Viraleze was going to be a massive commercial distraction, for suggesting 2 years ago that DEP-Docetaxel was going to be a commercial dud, for suggesting 1 year ago that the share price could tank if AstraZeneca terminated the AZD0466 trial, and for suggesting that 10 cents was on the cards prior to end of June 2024.
Go figure.
P.S. Whilst I feel vindicated for my often scathing assessments of the company’s many missteps, it doesn’t bring me joy. I first invested in Starpharma 20 years ago full of optimism and have been an off and on investor and trader in the stock over the journey. It wasn’t supposed to be like this.
P.S.S. I only own 1000 shares these days to remain a ‘shareholder’ but to be honest even at 11 cents I’m not selling my winners to buy more SPL yet.
P.S.S.S The new CEO is still not a shareholder despite the blackout period ending. I think I’ll wait until she sees value and finally purchases some shares.
